Aspivix closes $2M investment series
scroll south
Lausanne-based medtech Aspivix has secured over CHF 1.8M in a series A financing round. The newly acquired funds will accelerate product development and clinical research, and support scaling up production for the European market.
Aspivix develops non-traumatic, minimally invasive surgical instruments for gynaecology. Its first product is dedicated to allowing painless placement of intra-uterine contraceptive devices and other gynaecology procedures. Current procedures use forceps, causing pain and frequent bleeding. Aspivix’s device is a simple, patented, single-use medical instrument that reduces pain, eliminates the risk of lesions and bleeding, avoids the risk of cross-contamination, and streamlines the procedure significantly.The financing round was led by venture capital firm 4FO, with co-investment from ZKB and business angels BAS. Aspivix will use the proceeds to finalize the development and support the clinical trial of its product, boost its industrialization process and bring it to the European market.
The startup passed Venture Kick stage 2 in May 2018 and travelled to Boston with the Venture Leaders Life Sciences team earlier this year. “Being a Venture Leaders Life Science alumnus is a great privilege, which definitely laid the foundation for being able to successfully close this funding round. We are thankful for the outstanding help we received, giving a broad network and visibility to Aspivix,” said Mathieu Horras, CEO and co-founder of Aspivix SA
